Search

In radionuclide therapy with iodine-131 labelled pharmaceuticals, free [sup 131] I may be released and trapped by the thyroid, causing an undesirable radiation burden. To prevent this, stable iodide such as potassium iodide (KI) can be given to saturate the thyroid before [sup 131] I is administered. The guidelines of the European Association of Nuclear Medicine do not, however, recommend special precautions when administering [sup 131] I-lipiodol therapy for hepatocellular carcinoma. Nevertheless, some authors have reported [sup 131] I uptake in the thyroid as a consequence of such therapy. In this study, the influence of prophylactic KI on the thyroid uptake and dose (MIRD dosimetry) was prospectively investigated. [sup 131] I-lipiodol was given as a slow bolus selectively in the proper hepatic artery or hyperselectively in the right and/or left hepatic artery. Patients were prospectively randomised into two groups. One group received KI in a dose of 100 mg per day starting 2 days before [sup 131] I-lipiodol administration and continuing until 2 weeks after therapy (KI group; n=31), while the other group received no KI (non-KI group; n=37). Thyroid uptake was measured scintigraphically as a percentage of administered activity 7 days after [sup 131] I-lipiodol (n=68 treatments). The absorbed radiation dose to the thyroid was assessed by scintigraphy after 7 and 14 days using a mono-exponential fitting model and MIRD dosimetry (n=40 treatments). The mean activity of [sup 131] I-lipiodol administered was 1,835 MBq in a volume of 2 (n=17) or 4 (n=51) ml. Thyroid uptake was lower in the KI group, being 0.23%±0.06% of injected activity (n=31) compared with 0.42%±0.20% in the non-KI group (n=37); the mean thyroid dose was 5.5±1.6 Gy in the KI group (n=19) versus 11.9±5.9 Gy in the non-KI group (n=21). These differences were statistically significant (P<0.001). No effect of the amount of added cold lipiodol (4 vs 2 ml total volume) or selectivity... [ABSTRACT FROM AUTHOR]

The good tolerance of radionuclide therapy has frequently been proposed as a major advantage. This study explored the feasibility of using the EORTC QLQ-C30 questionnaire in palliative iodine-131 lipiodol therapy for hepatocellular carcinoma. Questionnaires were completed during interviews in which all symptoms, co-morbidity and medication were assessed at baseline within 1 week before [sup 131] I-lipiodol therapy, and subsequently after 1 and 3 months, in 20 patients treated with locoregional, intra-arterial [sup 131] I-lipiodol therapy with or without cisplatin. Principal observations were that (1) a number of important scales, i.e. overall quality of life, physical functioning and pain, worsened between 0 and 3 months after [sup 131] I-lipiodol therapy, irrespective of tumour response, and (2) the occurrence of clinical side-effects was associated with a negative impact on quality of life and physical functioning 1 and 3 months after [sup 131] I-lipiodol. The QLQ-C30 can be regarded as a feasible method for quality of life assessment in [sup 131] I-lipiodol therapy for hepatocellular carcinoma and possibly in other radionuclide therapies. These observations should be related to the impact of other treatment modalities on quality of life. [ABSTRACT FROM AUTHOR]